UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
June 6, 2000
------------------
(Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 1-11353 13-3757370
-------------- ----------- --------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
-------------------------------------------------------
(Address of principal executive offices)
336-229-1127
------------
(Registrant's telephone number, including area code)
<PAGE>
ITEM 5. OTHER EVENTS
On June 6, 2000, Laboratory Corporation of America-
Registered Trademark- Holdings (LabCorp-Registered Trademark-)
announced that it has called for redemption on July 7, 2000
all of its outstanding 8 1/2 percent Series A Convertible
Exchangeable Preferred Stock and 8 1/2 percent Series B
Convertible Pay-in-Kind Preferred Stock.
The redemption price for both the Series A and Series B
preferred stock is $52.83 per preferred share. The Series A
preferred stock is currently, and following June 30, 2000,
the Series B preferred will be, convertible into LabCorp
common stock at the rate of 1.81818 common shares per
preferred share at any time prior to 5:00 p.m., New York
City time, on July 6, 2000.
Also, LabCorp reported that Roche Holdings, Inc. has
indicated that it plans to sell up to 2.5 million shares of
common stock to a limited number of investors in order not
to become a majority shareholder of LabCorp. LabCorp has
filed a registration statement with the Securities and
Exchange Commission relating to this offer and sale by Roche
of LabCorp stock, but the registration statement has not yet
become effective. Such securities may not be sold nor may
offers to buy be accepted prior to the time the registration
becomes effective.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
INFORMATION AND EXHIBITS
(c) Exhibit
20 Press release of the Company dated
June 6, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Registrant)
By: /s/BRADFORD T. SMITH
------------------------------
Bradford T. Smith
Executive Vice President,
General Counsel, Secretary
and Compliance Officer
Date: June 7, 2000
<PAGE>